Loading clinical trials...
Loading clinical trials...
Phase 2a, Multi-center, Placebo-controlled, Randomized, Partially Blinded, Study Infused TK112690 or or Placebo Administered Along With Methotrexate Weekly for Four Consecutive Weeks to Patients With Recurrent or Residual SCCHN
Conditions
Interventions
TK-112690
Placebo TK-112690
Locations
3
India
Bangalore Cancer
Bangalore, Karnataka, India
Karnatak Cancer Therapy and Research Institute
Navanagar, Karnataka, India
Netaji Subhash Chandra Bose Cancer Hospital
Kolkata, West Bengal, India
Start Date
May 15, 2019
Primary Completion Date
October 10, 2019
Completion Date
March 31, 2020
Last Updated
August 25, 2023
NCT05853692
NCT06305000
NCT03983369
NCT07040969
NCT07047261
NCT06968520
Lead Sponsor
Tosk, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions